|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Interaction between microbiota and immunity in health and disease显示文摘The interplay between the commensal microbiota and the mammalian immune system development and function includes multifold interactions in homeostasis and disease.The microbiome plays critical roles in the training and development of major components of the host's innate and adaptive immune system,while the immune system orchestrates the maintenance of key features of host-microbe symbiosis.In a genetically susceptible host,imbalances in microbiota-immunity interactions under defined environmental contexts are believed to contribute to the pathogenesis of a multitude of immune-mediated disorders.Here,we review features of microbiome-immunity crosstalk and their roles in health and disease,while providing examples of molecular mechanisms orchestrating these interactions in the intestine and extra-intestinal organs.We highlight aspects of the current knowledge,challenges and limitations in achieving causal understanding of host immune-microbiome interactions,as well as their impact on immune-mediated diseases,and discuss how these insights may translate towards future development of microbiometargeted therapeutic interventions. | Danping Zheng Timur Liwinski Eran Elinav | 2020 | Cell Research2020，30，6： | 58 |
| 2 | Phages and their potential to modulate the microbiome and immunity显示文摘Bacteriophages(hence termed phages)are viruses that target bacteria and have long been considered as potential future treatments against antibiotic-resistant bacterial infection.However,the molecular nature of phage interactions with bacteria and the human host has remained elusive for decades,limiting their therapeutic application.While many phages and their functional repertoires remain unknown,the advent of next-generation sequencing has increasingly enabled researchers to decode new lytic and lysogenic mechanisms by which they attack and destroy bacteria.Furthermore,the last decade has witnessed a renewed interest in the utilization of phages as therapeutic vectors and as a means of targeting pathogenic or commensal bacteria or inducing immunomodulation.Importantly,the narrow host range,immense antibacterial repertoire,and ease of manipulating phages may potentially allow for their use as targeted modulators of pathogenic,commensal and pathobiont members of the microbiome,thereby impacting mammalian physiology and immunity along mucosal surfaces in health and in microbiomeassociated diseases.In this review,we aim to highlight recent advances in phage biology and how a mechanistic understanding of phage-bacteria-host interactions may facilitate the development of novel phage-based therapeutics.We provide an overview of the challenges of the therapeutic use of phages and how these could be addressed for future use of phages as specific modulators of the human microbiome in a variety of infectious and noncommunicable human diseases. | Sara Federici Samuel P.Nobs Eran Elinav | 2021 | Cellular & Molecular Immunology2021，18，4： | 7 |
| 3 | Role of the microbiome in non-gastrointestinal cancers显示文摘'The forgotten organ',the human microbiome,comprises a community of microorganisms that colonizes various sites of the human body.Through coevolution of bacteria,archaea and fungi with the human host over thousands of years,a complex host-microbiome relationship emerged in which many functions,including metabolism and immune responses,became codependent.This coupling becomes evident when disruption in the microbiome composition,termed dysbiosis,is mirrored by the development of pathologies in the host.Among the most serious consequences of dysbiosis,is the development of cancer.As many as 20% of total cancers worldwide are caused by a microbial agent.To date,a vast majority of microbiomecancer studies focus solely on the microbiome of the large intestine and the development of gastrointestinal cancers.Here,we will review the available evidence implicating microbiome involvement in the development and progression of non-gastrointestinal cancers,while distinguishing between viral and bacterial drivers of cancer,as well as 'local' and 'systemic','cancer-stimulating' and 'cancer-suppressing' effects of the microbiome.Developing a system-wide approach to cancer-microbiome studies will be crucial in understanding how microbiome influences carcinogenesis,and may enable to employ microbiome-targeting approaches as part of cancer treatment. | Meirav Pevsner-Fischer Timur Tuganbaev Mariska Meijer Sheng-Hong Zhang Zhi-Rong Zeng Min-Hu Chen Eran Elinav | 2016 | World Journal of Clinical Oncology2016，7，2： | 5 |
| 4 | NLRP6 Inflammasome Regulates Colonic Microbial Ecology and Risk for Colitis显示文摘 | Eran Elinav Till Strowig Andrew L. Kau Jorge Henao-Mejia Christoph A. Thaiss Carmen J. Booth David R. Peaper John Bertin Stephanie C. Eisenbarth Jeffrey I. Gordon Richard A. Flavell | 2011 | Cell2011，，5： | 3 |
| 5 | lnflammasome-mediated dysbiosis regulates progression of NAFLD and obesity显示文摘 | HENAO-MEJIA J ELINAV E JIN C | 2012 | Nature2012，，482： | 1 |
| 6 | Inflammasome-me- diated dysbiosis regulates progression of NAFLD and obesity 显示文摘 | Henao-Mejia J Elinav E Jin C | 2012 | Nature2012，482，7384： | 1 |
| 7 | Competitive inhibition of leptin signaling results in amelioration of liver fibrosis through modula- tion of stellate cell function显示文摘 | Elinav E Ali M Bruck R | 2009 | Hepatology2009，49，1： | 1 |
| 8 | In- flammasome-mediated dysbiosis regulates progression of NAFLD and obesity显示文摘 | Henao-Mejia J Elinav E Jin C Hao L | 2012 | Nature2012，482，7384： | 1 |
| 9 | Inflammasome media- ted dysbiosis regulates progression of NAFLD and obesity显示文摘 | Henao-Mejia J Elinav E Jin C | 2012 | Nature2012，482，17： | 1 |
| 10 | Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity显示文摘 | Henao-Mejia J Elinav E Jin C | 2012 | Nature2012，482，7384： | 1 |
| 11 | NLRP6 inflamma some regulates colonic microbial ecology and risk for coli tis显示文摘 | Elinav E Strowig T Kau A L | 2011 | Ce112011，145，5： | 1 |
| 12 | Intestinal lamina propria dendritic cell subsets have different origin and functions显示文摘 | Varol C Vallon-Eberhard A Elinav E | | Immunity0，，： | 1 |
| 13 | Suppression of hepatocel- lular carcinoma growth in mice via leptin, is associated with inhibi- tion of tumor cell growth and natural killer cell activation显示文摘 | Elinav E Abd-Einabi A Pappo O | 2006 | Journal ofhepatology2006，44，3： | 1 |
| 14 | NLRP6 inflammasomc regulates colonic microbial ecology and risk for colitis显示文摘 | Elinav E Strowig T Kau A L | 2011 | Cell2011，145，： | 1 |
| 15 | Regulation of the antimi-crobial response by NLR proteins显示文摘 | Elinav E Strowig T Henao-Mejia J | 2011 | Immunity2011，34，5： | 1 |
| 16 | Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4显示文摘 | Hu B Elinav E Huber S | 2010 | Proc Natl Acad Sci U S A2010，107，21： | 1 |
| 17 | Inflammasomes andmetabolic disease 显示文摘 | Henao-Mejia J Elinav E Thaiss CA | 2014 | Annu Rev Physiol2014，76，： | 1 |
| 18 | Inflamma- somes in health and disease 显示文摘 | Strowig T Henao-Mejia J Elinav E | 2012 | Nature2012，481，： | 1 |
| 19 | Distribution of fluconazole-resistant Candida bloodstream isolates among hospitals and inpatient services in Israel 显示文摘 | Ben-Ami R Rahav G Elinav H Kassis I Shalit I Gottes- man T Megged O Weinberger M Ciobotaro P Shitrit P Weber G Paz A Miron D Oren I Bishara J Block C Keller N Kontoyiannis DP Giladi M Israeli Candidaemia Study Group | 2013 | Clin Microbiol Infect2013，19，8： | 1 |
| 20 | Suppression of hepatocellular carcinoma growth in mice via leptin, is asso- ciated with inhibition of tumor cell growth and natural killer cell activation 显示文摘 | Elinav E Abd-Elnabi A Pappo O | 2006 | J Hepatol2006，44，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员